Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
Lancet (London, England)
|
June 8, 1974
Quantitative bone scanning: a method for assessing response of bone metastases to treatment
D L Citrin, R G Bessent, J B Tuohy, et al.
American Journal of Clinical Oncology
|
February 24, 2001
Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer
N B Haas, J Manola, G Hudes, et al.
Cancer
|
November 1, 1978
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement
T F Hogan, D L Citrin, B M Johnson, et al.
The British Journal of Surgery
|
March 1, 1975
The application of the 99Tcm phosphate bone scan to the study of breast cancer
D L Citrin, R G Bessent, W R Greig, et al.
Clinical Oncology
|
March 1, 1980
Serial scintiscanning in breast cancer: the indications and prognostic value
C M Furnival, L H Blumgart, D L Citrin, et al.
The British Journal of Radiology
|
September 1, 1980
Semi-quantitative analysis of the bone scan in acromegaly: correlation with human growth hormone values
I Fogelman, I D Hay, D L Citrin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 1, 1979
A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication
I Fogelman, D L Citrin, J H McKillop, et al.
European Journal of Nuclear Medicine
|
August 1, 1979
Semi-quantitative interpretation of the bone scan in metabolic bone disease: definition and validation of the metabolic index
I Fogelman, D L Citrin, J G Turner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 1, 1978
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease
I Fogelman, R G Bessent, J G Turner, et al.
Cancer
|
August 1, 1985
A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer
D L Citrin, M S Kies, C B Wallemark, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
Lancet (London, England)
|
June 8, 1974
Quantitative bone scanning: a method for assessing response of bone metastases to treatment
D L Citrin, R G Bessent, J B Tuohy, et al.
American Journal of Clinical Oncology
|
February 24, 2001
Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer
N B Haas, J Manola, G Hudes, et al.
Cancer
|
November 1, 1978
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement
T F Hogan, D L Citrin, B M Johnson, et al.
The British Journal of Surgery
|
March 1, 1975
The application of the 99Tcm phosphate bone scan to the study of breast cancer
D L Citrin, R G Bessent, W R Greig, et al.
Clinical Oncology
|
March 1, 1980
Serial scintiscanning in breast cancer: the indications and prognostic value
C M Furnival, L H Blumgart, D L Citrin, et al.
The British Journal of Radiology
|
September 1, 1980
Semi-quantitative analysis of the bone scan in acromegaly: correlation with human growth hormone values
I Fogelman, I D Hay, D L Citrin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
February 1, 1979
A clinical comparison of Tc-99m HEDP and Tc-99m MDP in the detection of bone metastases: concise communication
I Fogelman, D L Citrin, J H McKillop, et al.
European Journal of Nuclear Medicine
|
August 1, 1979
Semi-quantitative interpretation of the bone scan in metabolic bone disease: definition and validation of the metabolic index
I Fogelman, D L Citrin, J G Turner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 1, 1978
The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease
I Fogelman, R G Bessent, J G Turner, et al.
Cancer
|
August 1, 1985
A phase II study of high-dose estrogens (diethylstilbestrol diphosphate) in prostate cancer
D L Citrin, M S Kies, C B Wallemark, et al.
Page
of 6